Full Fed. Circ. Urged To Review Inequitable Conduct Ruling

Law360, New York (September 13, 2017, 9:17 PM EDT) -- Regeneron Pharmaceuticals Inc. asked the Federal Circuit on Tuesday for a full-court rehearing of its panel decision finding that its patent on a genetically modified mouse is unenforceable in part due to the inequitable conduct of litigators in its infringement case against Merus NV.

Regeneron argued that the appeals court’s 2-1 majority opinion issued in August had wrongly asserted that litigation misconduct reflected a “specific intent to deceive” the U.S. Patent and Trademark Office, thereafter cancelling the trial on the basis that the company had engaged...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Regeneron Pharmaceuticals v. Merus N.V.


Case Number

16-1346

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

December 18, 2015

Law Firms

Companies

Government Agencies

Patents

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.